Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Table 5 Patient outcomes according to the value of the initial and maximal trough concentration (Cmin)

Outcomes	No. of patients with initial C_min			No. of patients with maximal C_min
Outcomes	< 20 μg/mL	≥20 μg/mL	P-value	< 20 μg/mL	≥20 μg/mL	P-value
Early clinical response (n = 76)	23/37 (62.2%)	31/39 (79.5%)	0.096	–	–	–
Clinical success at the end of therapy (n = 76)	25/37 (67.6%)	30/39 (76.9%)	0.362	22/33 (66.7%)	33/43 (76.7%)	0.330
Microbiological success (n = 68)	22/33 (66.7%)	25/35 (71.4%)	0.671	20/31 (64.5%)	27/37 (73.0%)	0.452
28 days mortality (n = 76)	5/37 (13.5%)	2/39 (5.1%)	0.256	5/33 (15.2%)	2/43 (4.7%)	0.229

Eight patients in whom culture results after the start of therapy were not obtained were excluded from the microbiological success analysis

ISSN: 2050-6511